Journal
VACCINE
Volume 28, Issue 16, Pages 2806-2809Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.047
Keywords
Vaccines; Development; Target product profiles; Market
Categories
Funding
- Vaccine Modeling Initiative (VMI)
- Bill and Melinda Gates Foundation
Ask authors/readers for more resources
As history has demonstrated, post-approval obstacles can impede a vaccine's use and potentially lead to its withdrawal. Addressing these potential obstacles when changes in a vaccine's technology can still be easily made may improve a vaccine's chances of success. Augmented vaccine target product profiles (TPPs) can help vaccine scientists better understand and anticipate these obstacles and galvanize conversations among various vaccine stakeholders (e.g., scientists, marketers, business development managers, policy makers, public health officials, health care workers, third party payors, etc.) earlier in a vaccine's development. (c) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available